Predicting treatment response for ulcerative colitis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study aims to develop and validate a prediction model for how Korean patients with ulcerative colitis respond to biologic agents and small molecular agents like vedolizumab, ustekinumab, and tofacitinib. Eligible patients will undergo screening to collect demographic data, medical history, and disease characteristics, followed by baseline lower GI endoscopy and tissue collection. After treatment initiation, clinical and endoscopic responses will be evaluated at weeks 14 to 16 and 52, allowing researchers to create and validate models based on various clinical and biological data. The goal is to enhance personalized treatment strategies for ulcerative colitis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
* Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment

Exclusion Criteria:

* Not Korean ethnicity by family history
* Inflammatory Bowel Disease Unclassified
* Patients who already received colectomy due to ulcerative colitis

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Byong Duk Ye, MD, PhD
• Email: bdye@amc.seoul.kr
• Phone: 82230103180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Innovative Multidisciplinary and Virtual Care for IBD in Pregnancy

  This study tests a dedicated IBD pregnancy care model, including a new virtual approach, to see if it improves access and quality of care for pregnant people with Crohn's disease or ulcerative colitis.

  Recruiting at 5 sites Austin Health · Hobart and 6 other locations · NCT07916727

• A Probiotic Approach to Modulating Gut Microbiota in Mild-to-Moderate Ulcerative Colitis

  A specific probiotic given rectally will be tested in adults with mild-to-moderate ulcerative colitis to see if it can help manage symptoms.

  Recruiting Catholic University of the Sacred Heart · Roma, RM · NCT07724990

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• High Protein, High Fiber Diet for Ulcerative Colitis

  This study tests a high-protein, high-fiber diet to see if it helps people with ulcerative colitis by meeting protein needs and lowering harmful hydrogen sulfide production in the gut.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07520461

• Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics

  This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.

  Recruiting at 4 sites Phase 2 Athos Therapeutics Inc · Miami, Florida and 3 other locations · NCT07513181

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.